Skip to content
Clinical Trials – home
Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study looks at adults with moderately to severely active Crohn’s disease or ulcerative colitis, two conditions that cause inflammation of the digestive tract and can lead to abdominal pain, diarrhea, and weight loss. The investigational medicines are risankizumab and trosunilimab, which are given together as the combination known as ABBV-466. Each medicine works by blocking parts of the immune system that drive inflammation. Some participants will receive a placebo instead of the active drugs.

The purpose of the study is to see whether the combination works better and is safe compared with each medicine alone. Participants will receive a series of injections or infusions over several weeks. At scheduled visits doctors will ask about symptoms, perform simple stool checks, and use a thin camera (endoscopy) to look inside the intestine. The main goal is to find out how many people have endoscopic remission, meaning the camera shows no visible inflammation after about 28 weeks, while safety is monitored by recording any unwanted effects.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Baseline Assessments

    After agreeing to take part, you will complete initial medical tests, including blood work, stool samples, and an endoscopic examination of the intestine. These measurements establish your health status before any study medication is given.

    Your disease type (Crohn’s disease or ulcerative colitis) and severity will be recorded to determine eligibility for the trial.

  2. Step 2

    Randomization and First Study Medication Administration

    You will be randomly assigned to receive either the combination of risankizumab and trosunilimab, a single‑drug regimen of risankizumab, or the corresponding placebo(s).

    The first dose will be given by intravenous, subcutaneous, or intramuscular injection according to the study protocol. The exact amount of each drug is defined by the trial and is not disclosed here.

  3. Step 3

    Ongoing Study Medication Doses

    Additional doses of the assigned medication(s) will be administered at regular intervals, typically every four weeks, until the end of week 28.

    If you are receiving the combination, both risankizumab and trosunilimab will be given together; if you are in a monotherapy group, you will receive only risankizumab and a matching placebo.

  4. Step 4

    Mid‑Study Evaluation

    At week 12, you will undergo a repeat endoscopic examination to assess the condition of the intestine.

    Questionnaires about stool frequency, abdominal pain, and overall symptoms will be completed, and safety labs will be drawn to monitor for any adverse events.

  5. Step 5

    Continued Medication and Safety Monitoring

    You will continue to receive study medication according to the schedule and will attend clinic visits for routine safety assessments, including blood tests and symptom checks.

    Any side effects or health changes will be recorded by the study team.

  6. Step 6

    Final Evaluation

    At week 28, a final endoscopic examination will be performed to determine whether endoscopic remission has been achieved.

    Additional clinical assessments, such as disease activity scores and laboratory tests, will be completed to evaluate the overall effectiveness of the treatment.

  7. Step 7

    End of Study Procedures

    After the week‑28 visit, the study medication will be stopped, and you will receive instructions for any required follow‑up care.

    A summary of your participation and any final safety information will be provided.

Who can join the trial?

7 criteria

  • Must be an adult (18 years or older) and can be either male or female.
  • Must have a confirmed diagnosis of Crohn’s disease or ulcerative colitis that was made at least 90 days before starting the study.
  • If you have Crohn’s disease, you need a Crohn’s Disease Activity Index (CDAI) score of 220 or higher. The CDAI is a number that doctors use to show how active the disease is.
  • If you have Crohn’s disease, an endoscopy (a camera looking inside the intestine) must show inflammation with a Simple Endoscopic Score for Crohn’s Disease (SES‑CD) of at least 6 for disease in the colon or both colon and ileum, or at least 4 if the disease is only in the ileum. This score measures how much the lining of the intestine is inflamed.
  • If you have Crohn’s disease, you must have tried at least one medication or other therapy for the disease that did not work well enough (a treatment “failure”).
  • If you have ulcerative colitis, you need an active disease with a modified Mayo Score (mMS) between 5 and 9 points, and an endoscopic subscore (ESS) of 2 or 3. The Mayo Score is a number that combines symptoms and findings from the colonoscopy, and the endoscopic subscore shows how much inflammation is seen on the colonoscopy.
  • If you have ulcerative colitis, you must have tried at least one medication or other therapy for the disease that did not work well enough (a treatment “failure”).

Who cannot join the trial?

8 criteria

  • If you have shown an intolerance (cannot tolerate) to medicines that block a protein called p19 IL‑23 (including the drug risankizumab), you cannot join the study.
  • If you have taken any experimental (investigational) drug within the last 30 days, or for a longer time based on how long the drug stays in your body (its “half‑life”), before the first dose of the study medication, you cannot join.
  • If you have received any other advanced therapies (called biologics, which are lab‑made proteins, or small‑molecule drugs, which are chemical pills) for your condition within the time period required by the study before the first dose, you cannot join.
  • If you had surgery to remove part of your bowel within the past 3 months before the study starts, you cannot join.
  • If you have Crohn’s disease and have had more than three prior surgeries to remove parts of your bowel, you cannot join.
  • If you have Crohn’s disease and have had a small‑bowel surgery that removed more than 100 cm (about 1 meter) of intestine, you cannot join.
  • If you have ulcerative colitis and have already had a colectomy (removal of the colon, either total or partial), you cannot join.
  • If you have ulcerative colitis and the disease is limited to less than 10 cm of the rectum, you cannot join.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Risankizumab

    is a laboratory‑made protein that attaches to a part of the immune system called interleukin‑23. By blocking this signal, it helps reduce the inflammation that causes symptoms of Crohn’s disease and ulcerative colitis. In the study it is given by injection under the skin or into a vein.

  • ABBV-382

    is a human‑engineered antibody that targets a molecule called alpha4beta7 integrin. This molecule normally guides immune cells to the lining of the gut. By blocking it, ABBV-382 prevents those immune cells from entering the intestine, which can lower gut inflammation. It is administered as an injection or infusion.

  • ABBV-466

    is a combination therapy that includes both risankizumab and trosunilimab, another monoclonal antibody. The two drugs work together: risankizumab blocks the interleukin‑23 pathway, while trosunilimab targets a different part of the immune response. Using them together may give a stronger effect in controlling moderate to severe Crohn’s disease or ulcerative colitis. This combination is also given by injection or infusion.

What is already known about the treatment

  • Risankizumab

    This medication is given as a solution for injection or infusion, usually by subcutaneous injection. It is an approved drug that is listed in medical references for the treatment of moderate to severe Crohn’s disease, ulcerative colitis, and plaque psoriasis. Risankizumab works by attaching to a protein called interleukin‑23, stopping it from triggering inflammation in the gut. It belongs to the class of monoclonal antibodies known as IL‑23 inhibitors.

  • Anti‑α4β7 integrin monoclonal antibody

    The drug is supplied as a solution for injection or infusion and can be administered intravenously or subcutaneously. It is still an investigational product and has not yet received regulatory approval, being studied in clinical trials for inflammatory bowel diseases. It blocks the α4β7 integrin on immune cells, which prevents these cells from moving into the intestine and causing inflammation. This agent is classified as a humanised IgG1 kappa monoclonal antibody that acts as an integrin antagonist.

Investigated diseases

  • Crohn's disease

    A chronic inflammatory condition that can affect any part of the gastrointestinal tract, most often the small intestine and colon. It causes swelling and ulceration, leading to abdominal pain, diarrhea, and weight loss. Over time the inflammation may create narrowings (strictures) or abnormal connections (fistulas) between organs. Symptoms tend to appear in cycles, with periods of worsening called flares followed by calmer periods. The inflammation can extend through several layers of the intestinal wall.

  • Ulcerative colitis

    A chronic inflammatory disease that is limited to the colon and rectum. It produces ulceration of the inner lining, causing bloody diarrhea, urgency, and abdominal cramps. The condition usually begins in the rectum and can spread continuously upward through the colon. As the disease progresses, a larger portion of the colon may become inflamed, increasing the frequency of symptoms. Like Crohn's disease, it shows cycles of flare and remission.

Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-525959-86-00Protocol codeM26-266-1Estimated enrolment777 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.